AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
Rhea-AI Summary
AIM ImmunoTech (NYSEAM:AIM) announced that holders will exercise existing Class A–F warrants to buy up to 8,719,928 common shares at $0.48 per share for gross proceeds of approximately $4.2 million, before fees. The company plans to use net proceeds for working capital and general corporate purposes.
In exchange, exercising holders will receive private Replacement Warrants exercisable, upon stockholder approval, into up to 17,439,856 shares at $0.60 per share for five years. The offering is expected to close on or about May 8, 2026, subject to customary closing conditions.
AI-generated analysis. Not financial advice.
Positive
- Gross proceeds of approximately $4.2 million from warrant exercises
- Existing warrants exercised at a reduced price of $0.48 per share
- Company will use net proceeds for working capital and general corporate purposes
- Registration statements cover shares issuable upon exercise of the Existing Warrants
Negative
- Issuance of up to 8,719,928 common shares on exercise of Existing Warrants (potential dilution)
- Replacement Warrants convertible into up to 17,439,856 shares at $0.60 per share (additional dilution risk)
- Replacement Warrants and underlying shares are unregistered in a private placement until registration or exemption
News Market Reaction – AIM
On the day this news was published, AIM declined 39.66%, reflecting a significant negative market reaction. Argus tracked a trough of -46.3% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $4.56M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum data flags only HCWB with a move of about 4.56% up and no news, while AIM’s setup reflects company-specific financing activity rather than a coordinated biotechnology sector move.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 06 | Rights offering closing | Neutral | +4.3% | Announced closing of rights offering with about $1.8M total subscriptions. |
| Mar 04 | Rights offering results | Neutral | -1.3% | Reported preliminary rights offering results with estimated $1.8M subscriptions. |
| Feb 25 | Rights period extension | Neutral | -4.7% | Extended subscription period of ongoing rights offering to March 3, 2026. |
| Feb 12 | Rights offering terms | Neutral | +58.2% | Detailed rights offering to sell up to 12,000 Units for $12M gross proceeds. |
| Feb 11 | Rights offering launch | Neutral | -13.5% | Commenced rights offering targeting $12M with preferred shares and warrants. |
Recent capital-raising and rights offering headlines often produced sizable but mixed price reactions.
Over the past few months, AIM has repeatedly used equity-linked offerings to raise capital. A February rights offering launch targeting up to $12.0 million saw a large price swing, followed by extensions and revised terms. By early March, preliminary and final rights offering updates pointed to about $1.8 million in gross proceeds. Today’s warrant exercise agreement continues this pattern of financing activity, adding further equity-linked dilution potential on top of prior preferred and warrant structures.
Historical Comparison
In recent months AIM issued multiple offering-related updates, averaging a 8.61% move on those days. This warrant-exercise financing fits that ongoing pattern of equity-linked capital raises.
Recent activity shows a sequence from announcing and revising a rights offering, through preliminary and final results, to today’s additional warrant exercise structure layered on prior preferred and warrant financing.
Regulatory & Risk Context
AIM has an effective S-3/A shelf registered on 2025-06-27, authorizing up to $100 million across various securities. It has been used at least three times via prospectus supplements, giving the company flexibility to continue raising capital that could dilute existing shareholders depending on security type and size.
Market Pulse Summary
The stock dropped -39.7% in the session following this news. A negative reaction despite the cash infusion would fit concerns seen in earlier offering cycles, where new equity-linked securities introduced additional dilution risk alongside fundraising. This transaction adds up to 17,439,856 Replacement Warrant shares on top of 8,719,928 exercised shares. With an effective $100 million shelf and multiple recent offerings, the pattern of repeated capital raises could weigh on sentiment even as it extends funding.
Key Terms
warrants financial
placement agent financial
accredited investors financial
registration statements regulatory
section 4(a)(2) regulatory
private placement financial
unregistered warrants financial
AI-generated analysis. Not financial advice.
OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class B, Class C, Class D, Class E and Class F Warrants (the “Existing Warrants”) to purchase up to an aggregate of 8,719,928 shares of common stock at a reduced exercise price of
Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this transaction.
The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to registration statements which were filed and declared effective by the Securities and Exchange Commission (the “SEC”).
In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new unregistered warrants (the “Replacement Warrants”) to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”). The Replacement Warrants will be exercisable, beginning on the effective date of stockholder approval, into an aggregate of up to 17,439,856 shares of common stock, at an exercise price of
The offering is expected to close on or about May 8, 2026, subject to satisfaction of customary closing conditions.
The Replacement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the 1933 Act and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Replacement Warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. For those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “believes,” “expects,” “intends,” “may,” “will,” “plans,” “potential,” “anticipates,” or similar expressions. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include: statements relating to the anticipated closing date, the timing of commencement, enrollment, completion, and results of clinical trials; IP expansion and regulatory progress; and timing for receiving government approvals, if at all. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.
For a detailed discussion of risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. These filings are available at www.sec.gov and www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference into this press release and is included for reference purposes only.
CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com